NMR
Nomura Holdings Inc
$9.80
▲ 4.4%Updated Today 3:42 PM ET
NMR at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 36/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 43.0% over the last 12 months
Market Cap
$28.37B
P/E
11.79x
Forward P/E (est.)
11.02x
ROE
10.1%
Revenue Growth
0.5%
EPS Growth
7.0%
Profit Margin
7.6%
FCF Yield
—
Debt / Equity
10.53x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
3.4%
Implied Growth (rev. DCF)
—
Rating Score
36/100
Nomura Holdings Inc (NMR) is a large-cap company in the Financial Services industry, part of the Financials sector of the S&P 500, with a market value around $28.37B.
In its latest reported year it generated about $31.88B in revenue and $2.43B in net profit.
Our model rates NMR Weak (36/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what NMR's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. NMR trades near $9.80, above its 50-day average ($8.35) and 200-day average ($8.10). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 67 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. NMR's is $0.22 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month NMR found buyers near $8.38 (support) and sellers near $9.32 (resistance); its 52-week range is $6.21–$9.58. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
31.4%
Revenue moved from $11.49B in 2017 to $31.88B in 2026, a 12.0% compound annual growth rate. The most recent year was roughly flat (0.5%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
45.5%
Operating Margin
11.3%
Net Margin
7.6%
ROE
10.1%
Nomura Holdings Inc keeps about 7.6% of each sales dollar as net profit, with a 45.5% gross margin and 11.3% operating margin. Return on equity is 10.1%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$113.63B
Net Debt
$106.47B
Net Debt / EBITDA
—
Debt / Equity
10.53x
Leverage: debt-to-equity is 10.5x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $113.63B of total debt against $7.16B of cash.
Operating CF
-$5.65B
Free Cash Flow
-$8.02B
FCF Margin
-25.2%
In the latest year Nomura Holdings Inc produced about -$5.65B of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Dividend yield
3.4%
Total paid (latest FY)
$1.20B
History on record
10 years
free cash flow was negative in the latest year — the dividend is being financed
50% of net income paid out
total dividends increased 3 years in a row
payout was cut at least once in the last 10 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
11.79x
P/S
0.89x
P/B
1.01x
EV / EBITDA
—
NMR trades at 11.8x trailing earnings (about 11.0x on estimated forward earnings), 0.9x sales, and 1.0x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Where NMR sits versus its Financials sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 141 Financials companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How NMR stacks up against its Financials peers — valuation, profitability, and growth versus the sector median.
In the Financials sector (289 S&P 500 companies), NMR ranks #132 of 289 by our overall rating. It trades at a discount versus the sector on earnings (11.8x P/E vs. 15.3x median) with a lower return on equity (10.1% vs. 13.6%) and slower revenue growth (0.5% vs. 15.9%).
P/E vs sector
11.8x
median 15.3x
ROE vs sector
10.1%
median 13.6%
Growth vs sector
0.5%
median 15.9%
Sector rank
#132
of 289 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Financials companies by sub-industry and size. Sector median is across all 289 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $9.80 today · expected CAGR -6% – 5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $32.84B | $33.82B | $34.84B | $35.88B | $36.96B |
| Net income | $2.63B | $2.71B | $2.79B | $2.87B | $2.96B |
| EPS | $0.91 | $0.93 | $0.96 | $0.99 | $1.02 |
| Share price (low) | $6.35 | $6.54 | $6.74 | $6.94 | $7.15 |
| Share price (high) | $10.89 | $11.22 | $11.55 | $11.90 | $12.26 |
| CAGR (low–high) | -35% / 11% | -18% / 7% | -12% / 6% | -8% / 5% | -6% / 5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for NMR:
- Pays a 3.4% dividend on top of any price gains.
- As an established S&P 500 member in Financials, it brings scale and a long operating history.
The case against NMR:
- Revenue growth is slow (0.5%), limiting the upside engine.
- Elevated leverage (debt/equity 10.5x) adds financial risk.
- Our model's overall read is Weak (36/100).
Balance-sheet risk — debt/equity of 10.5x magnifies the impact of higher rates or weaker earnings.
Growth risk — sluggish revenue (0.5%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Nomura Holdings Inc is a large-cap financials business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 11.8x earnings, which our model scores Weak (36/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 14 Wall Street analysts covering NMR recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+3 pts of buy ratings).
Latest SEC Filings
NMR's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
NMR — frequently asked questions
Is NMR a good stock to buy?
We don't give buy or sell advice. Our model rates Nomura Holdings Inc Weak (36/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is NMR's rating on The Stocks School?
Nomura Holdings Inc currently scores 36/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does NMR's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Nomura Holdings Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for NMR calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this NMR analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell NMR. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.